Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Welcome and Introduction to Vi3C

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mar

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Welcome and Introduction to Vi3C

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer

Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

Women More Likely to Survive Cancer—But Suffer More Severe Side Effects

Forgotten Lessons From South Africa

Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC